TITLE:
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)

CONDITION:
Gastrointestinal Cancer

INTERVENTION:
AMG 706

SUMMARY:

      This study will determine the safety and effectiveness of AMG 706 in patients with advanced
      GIST.
    

DETAILED DESCRIPTION:

      Expanded Access: Amgen provides expanded access for this clinical trial. Contact the Amgen
      Call Center (866-572-6436) for more information.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  Age  18 years;

          -  Disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) during
             previous treatment with imatinib mesylate at least 600 mg daily for at least 8 weeks,
             as per two independently assessed prestudy computerized tomography (CT) scans;

          -  Presence of at least one measurable (per RECIST)

          -  Progressing tumor lesion not previously treated with radiotherapy or embolization and
             evaluable by CT scan or magnetic resonance imaging (MRI);

          -  Karnofsky performance status  60;

          -  imatinib treatment terminated at least 7 days before study day 1;

          -  Adequate hepatic, renal, and cardiac function.

        Exclusion criteria:

          -  Prior malignancy (other than GIST, in situ cervical cancer, or basal cell cancer of
             the skin) unless treated with curative intent and without evidence of disease for  3
             years; cardiac disease including myocardial infarction, unstable angina, and
             congestive heart failure (New York Heart Association class > II),

          -  uncontrolled hypertension (systolic > 145 mmHg or diastolic > 85 mmHg),

          -  History of arterial thrombosis or deep vein thrombosis (including pulmonary embolus)
             within 1 year of study day 1;

          -  Absolute neutrophil count < 1.5x109/L, platelet count < 100x109/L, hemoglobin < 9.0
             g/dL;

          -  Prior treatment with motesanib diphosphate or other KIT (except imatinib) or VEGF
             inhibitors.

          -  The study was approved by the institutional review board of each participating
             institution, and all patients provided written informed consent before any
             study-related procedures were performed.
      
